{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:03:05Z","timestamp":1791277385042,"version":"4.1.0"},"reference-count":28,"publisher":"Pharmaceutical Society of Japan","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,5,17]]},"DOI":"10.1248\/bpb.b24-00762","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T22:09:54Z","timestamp":1747433394000},"page":"641-649","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of Long Coronavirus Disease in Japan: A Nationwide Study of Symptom-Associated Drug Prescriptions"],"prefix":"10.1248","volume":"48","author":[{"given":"Yuka","family":"Kogure","sequence":"first","affiliation":[{"name":"Laboratory of Pharmacy Practice and Science IV, Research and Education Center for Clinical Pharmacy, Kitasato University School of Pharmacy, 6\u2013100 Arai, Kitamoto, Saitama 364\u20138501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Ando","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacy Practice and Science IV, Research and Education Center for Clinical Pharmacy, Kitasato University School of Pharmacy, 6\u2013100 Arai, Kitamoto, Saitama 364\u20138501, Japan"},{"name":"Department of Pharmacy, Kitasato University Medical Center, 6\u2013100 Arai, Kitamoto, Saitama 364\u20138501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoka","family":"Sakamaki","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacy Practice and Science IV, Research and Education Center for Clinical Pharmacy, Kitasato University School of Pharmacy, 6\u2013100 Arai, Kitamoto, Saitama 364\u20138501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacy Practice and Science IV, Research and Education Center for Clinical Pharmacy, Kitasato University School of Pharmacy, 6\u2013100 Arai, Kitamoto, Saitama 364\u20138501, Japan"},{"name":"Department of Pharmacy, Kitasato University Medical Center, 6\u2013100 Arai, Kitamoto, Saitama 364\u20138501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Mehandru S, Merad M. Pathological sequelae of long-haul COVID. <i>Nat. Immunol.<\/i>, <b>23<\/b>, 194\u2013202 (2022).","DOI":"10.1038\/s41590-021-01104-y"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Monje M, Iwasaki A. The neurobiology of long COVID. <i>Neuron<\/i>, <b>110<\/b>, 3484\u20133496 (2022).","DOI":"10.1016\/j.neuron.2022.10.006"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Raman B, Bluemke DA, Luscher TF, Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. <i>Eur. Heart J.<\/i>, <b>43<\/b>, 1157\u20131172 (2022).","DOI":"10.1093\/eurheartj\/ehac031"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. <i>Nat. Rev. Microbiol.<\/i>, <b>21<\/b>, 133\u2013146 (2023).","DOI":"10.1038\/s41579-022-00846-2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. <i>Lancet Infect. Dis.<\/i>, <b>22<\/b>, e102\u2013e107 (2022).","DOI":"10.1016\/S1473-3099(21)00703-9"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Subramanian A, Nirantharakumar K, Hughes S, <i>et al<\/i>. Symptoms and risk factors for long COVID in non-hospitalized adults. <i>Nat. Med.<\/i>, <b>28<\/b>, 1706\u20131714 (2022).","DOI":"10.1038\/s41591-022-01909-w"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Silva Andrade B, Siqueira S, de Assis Soares WR, de Souza Rangel F, Santos NO, Dos Santos Freitas A, Ribeiro da Silveira P, Tiwari S, Alzahrani KJ, Goes-Neto A, Azevedo V, Ghosh P, Barh D. Long-COVID and post-COVID health complications: an up-to-date review on clinical conditions and their possible molecular mechanisms. <i>Viruses<\/i>, <b>13<\/b>, 700 (2021).","DOI":"10.3390\/v13040700"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. <i>BMJ<\/i>, <b>374<\/b>, n1648 (2021).","DOI":"10.1136\/bmj.n1648"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Huang C, Huang L, Wang Y, <i>et al<\/i>. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. <i>Lancet<\/i>, <b>401<\/b>, e21\u2013e33 (2023).","DOI":"10.1016\/S0140-6736(23)00810-3"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Heesakkers H, van der Hoeven JG, Corsten S, Janssen I, Ewalds E, Simons KS, Westerhof B, Rettig TCD, Jacobs C, van Santen S, Slooter AJC, van der Woude MCE, van den Boogaard M, Zegers M. Clinical outcomes among patients with 1-year survival following intensive care unit treatment for COVID-19. <i>JAMA<\/i>, <b>327<\/b>, 559\u2013565 (2022).","DOI":"10.1001\/jama.2022.0040"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Asakura T, Kimura T, Kurotori I, Kenichi K, Hori M, Hosogawa M, Saijo M, Nakanishi K, Iso H, Tamakoshi A. Case-control study of Long COVID, Sapporo, Japan. <i>Emerg. Infect. Dis.<\/i>, <b>29<\/b>, 956\u2013966 (2023).","DOI":"10.3201\/eid2905.221349"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Miyazato Y, Morioka S, Tsuzuki S, Akashi M, Osanai Y, Tanaka K, Terada M, Suzuki M, Kutsuna S, Saito S, Hayakawa K, Ohmagari N. Prolonged and late-onset symptoms of Coronavirus Disease 2019. <i>Open Forum Infect. Dis.<\/i>, <b>7<\/b>, ofaa507 (2020).","DOI":"10.1093\/ofid\/ofaa507"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Watanabe A, Iwagami M, Yasuhara J, Takagi H, Kuno T. Protective effect of COVID-19 vaccination against long COVID syndrome: a systematic review and meta-analysis. <i>Vaccine<\/i>, <b>41<\/b>, 1783\u20131790 (2023).","DOI":"10.1016\/j.vaccine.2023.02.008"},{"key":"14","unstructured":"14) The ministry of internal affairs and communications in Japan. \u201cVisualizing the data: information on COVID-19 infection.\u201d: &lt;https:\/\/covid19.mhlw.go.jp\/extensions\/public\/en\/index.html&gt;, accessed 2 July 2024."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Daugherty SE, Guo Y, Heath K, Dasmarinas MC, Jubilo KG, Samranvedhya J, Lipsitch M, Cohen K. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. <i>BMJ<\/i>, <b>373<\/b>, n1098 (2021).","DOI":"10.1136\/bmj.n1098"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Kinugasa Y, Llamas-Covarrubias MA, Ozaki K, Fujimura Y, Ohashi T, Fukuda K, Higashiue S, Nakamura Y, Imai Y. Post-Coronavirus Disease 2019 Syndrome in Japan: an observational study using a medical database. <i>JMA J.<\/i>, <b>6<\/b>, 416\u2013425 (2023).","DOI":"10.31662\/jmaj.2023-0048"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Sakamaki K, Shibuya K, Ando W. Insights from a multicenter nationwide cohort analysis in Japan on the association of underlying conditions and pharmacological interventions with COVID-19 disease severity. <i>Discov. Public Health<\/i>, <b>21<\/b>, 112 (2024).","DOI":"10.1186\/s12982-024-00225-7"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Cohen K, Ren S, Heath K, Dasmarinas MC, Jubilo KG, Guo Y, Lipsitch M, Daugherty SE. Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study. <i>BMJ<\/i>, <b>376<\/b>, e068414 (2022).","DOI":"10.1136\/bmj-2021-068414"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Hawes MT, Szenczy AK, Klein DN, Hajcak G, Nelson BD. Increases in depression and anxiety symptoms in adolescents and young adults during the COVID-19 pandemic. <i>Psychol. Med.<\/i>, <b>52<\/b>, 3222\u20133230 (2022).","DOI":"10.1017\/S0033291720005358"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Borch L, Holm M, Knudsen M, Ellermann-Eriksen S, Hagstroem S. Long COVID symptoms and duration in SARS-CoV-2 positive children\u2014a nationwide cohort study. <i>Eur. J. Pediatr.<\/i>, <b>181<\/b>, 1597\u20131607 (2022).","DOI":"10.1007\/s00431-021-04345-z"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Radtke T, Ulyte A, Puhan MA, Kriemler S. Long-term symptoms after SARS-CoV-2 infection in children and adolescents. <i>JAMA<\/i>, <b>326<\/b>, 869\u2013871 (2021).","DOI":"10.1001\/jama.2021.11880"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, Lekoubou A, Oh JS, Ericson JE, Ssentongo P, Chinchilli VM. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. <i>JAMA Netw. Open<\/i>, <b>4<\/b>, e2128568 (2021).","DOI":"10.1001\/jamanetworkopen.2021.28568"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re\u2019em Y, Redfield S, Austin JP, Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. <i>EClinicalMedicine<\/i>, <b>38<\/b>, 101019 (2021).","DOI":"10.1016\/j.eclinm.2021.101019"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Li M, Sun Z, Zhang H, Liu Z. Recent advances on polaprezinc for medical use. <i>Exp. Ther. Med.<\/i>, <b>22<\/b>, 1445 (2021).","DOI":"10.3892\/etm.2021.10880"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Pang Z, Tang A, He Y, Fan J, Yang Q, Tong Y, Fan H. Neurological complications caused by SARS-CoV-2. <i>Clin. Microbiol. Rev.<\/i>, <b>37<\/b>, 0013124 (2024).","DOI":"10.1128\/cmr.00131-24"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Tokumasu K, Ueda K, Honda H, Sunada N, Sakurada Y, Matsuda Y, Nakano Y, Hasegawa T, Otsuka Y, Obika M, Hagiya H, Kataoka H, Otsuka F. Application of Kampo medicines for treatment of general fatigue due to Long COVID. <i>Medicina<\/i> (Kaunas), <b>58<\/b>, 730 (2022).","DOI":"10.3390\/medicina58060730"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Takayama S, Kikuchi A, Makino T, Kainuma M, Namiki T, Ito T. Basic pharmacological mechanisms and clinical evidence of the efficacy of hochuekkito against infectious diseases and its potential for use against COVID-19. <i>Tradit. Kampo Med.<\/i>, <b>8<\/b>, 3\u201321 (2021).","DOI":"10.1002\/tkm2.1264"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Sudre CH, Murray B, Varsavsky T, <i>et al<\/i>. Attributes and predictors of long COVID. <i>Nat. Med.<\/i>, <b>27<\/b>, 626\u2013631 (2021).","DOI":"10.1038\/s41591-021-01292-y"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/5\/48_b24-00762\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T03:41:06Z","timestamp":1747453266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/5\/48_b24-00762\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b24-00762","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"article-number":"b24-00762"}}